ADAM17 and cancer: In comparison to the wildtype, cancer-associated mutations of ADAM17 within the membrane-proximal- (D616N and D657A) and the cytoplasmic-domain (R725H) showed a slightly reduced, but not significantly impaired cell surface activity (Figure 2E).